Prophylactic Cerclage for Twin Pregnancy With Shortened Cervix

Protective Value of Cervical Cerclage Against Preterm Birth in Twin Pregnancy With Short Cervix. A Randomized Controlled Trial.

This randomized controlled trial is aimed to evaluate pregnancy and neonatal outcomes in twin pregnancies, in which a cervical cerclage is placed due to the shortening of the cervix with or without visible fetal membranes.

Study Overview

• Status: Completed
• Conditions: Preterm Birth; Twin Pregnancy With Antenatal Problem; Cervical Shortening
• Intervention / Treatment: Procedure: cervical cerclage

Detailed Description

Introduction Multiple pregnancies are high-risk pregnancies and usually associated with an increased risk of neonatal morbidity and mortality, mainly due to preterm births. Preterm births occur in 50% of twin pregnancies and the mean gestational age for delivery is 35.3 weeks. Ten percent of all twin births take place before 32 weeks of gestation.1 Preterm births are responsible for more than 70% of all neonatal and infant mortality.2 Prematurity can have serious consequences for the child, such as hearing difficulties, vision impairment, learning disabilities, reduced IQ, and cerebral palsy. A cervical length of ≤25 mm in twin pregnancies is a good predictor of a spontaneous preterm birth when measured around 24 weeks of gestation.3,4 Numerous interventions have been attempted in order to prevent preterm births in twin gestations, but until now, no intervention has been effective. Use of cerclage in twin pregnancies is controversial. Some experts claim that placing a cervical cerclage could increase the risk of preterm births.5 However, there is growing evidence of beneficial effect of applying cervical cerclage. Based on a few, small, controlled trials, cervical cerclage may extend the pregnancy, if it is applied to a cervix of less than 15 mm.6,7 Such practice is still in need for further validation by well-structured and powered randomized controlled trials.

Rationale:

Pregnant in twins with history suggesting cervical weakness and evidence of shortened cervix in the current pregnancy might get benefit from mechanical support by cervical cerclage in trial to reduce the risk of preterm birth.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Sharkia
    • Zagazig, Sharkia, Egypt, 44519
      • Faculty of Medicine, Zagazig University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age between 18-45 years.
• Dichorionic twins.
• Transvaginal sonographic cervical length is <25 mm with or without internal os dilatation ≥10 mm at 14-20 weeks gestational age.
• Asymptomatic.

Exclusion Criteria:

• Triplets and quadruplets.
• Monochorionic twins.
• Threatened/ inevitable miscarriage
• Bulging membranes through the external os.
• Extremes of age.
• Major fetal anomalies.
• Known cases with uterine anomalies e.g. bicornuate uterus, uterus didelphis… etc.
• Fetal demise.
• Fetal reduction in the current pregnancy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cerclage group; cervical cerclage between 14 and 20 weeks will be done by one of the three authors.	Procedure: cervical cerclage; McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
No Intervention: No Cerclage group; Routine follow up without cerclage

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence of preterm birth at ≤33+6, and ≤31+6 weeks with cervical length ≤25 mm	Rate of preterm births stratified by gestational age inside the included women	Immediate reporting of cases at time of delivery through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subgroup analysis for the risk of preterm birth at ≤33+6, and ≤31+6 weeks with cervical length ≤15 mm	subgroup analysis for rate of preterm births for very short cervix	Immediate reporting of cases at time of delivery through study completion, an average of 1 year
The incidence of miscarriage.	rate of missed, inevitable and complete miscarriages	Immediate reporting of cases at time of miscarriage through study completion, an average of 1 year
Incidence of cervico-vaginal infection	Rate of infections diagnosed during pregnancy by patient complaint, clinical examination and confirmed by culture and sensitivity).	after confirmation of infection through study completion, an average of 1 year
Neonatal outcomes in both groups	Rate of untoward early neonatal outcomes respiratory distress, IVH, necrotizing enterocolitis, sepsis, NICU admission	early neonatal through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Zagazig University
• Investigators: Principal Investigator: Mohamed Lashiin, M.D., Zagazig University; Principal Investigator: Amro El Nemr, M.D., Zagazig University

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2021
• Primary Completion (Actual): August 27, 2024
• Study Completion (Actual): October 31, 2024

Study Registration Dates

• First Submitted: December 11, 2021
• First Submitted That Met QC Criteria: April 16, 2022
• First Posted (Actual): April 21, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 24, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Obstetric Labor, Premature; Obstetric Labor Complications; Pregnancy Complications; Premature Birth
• Other Study ID Numbers: ZU-IRB #8090/17-10-2021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No